Quizartinib ≥95%

Supplier: ADIPOGEN CORP MS
Warning

Synonyms: AC220

SYN-1003-M050 SYN-1003-M005 SYN-1003-M001 SYN-1003-M010
102991-194EA 1330.62 USD
102991-194 102991-190 102991-192 102991-188
Quizartinib ≥95%
Quizartinib

Quizartinib (AC220) is a second-generation FLT3 inhibitor that has shown promising activity in AML in Phase II clinical trials. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5µM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Recently, AC220 has also been shown to be an effective inhibitor of ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5µM and from 0.5 to 10µM, respectively, and inhibited-IAAP photolabeling of ABCG2 and ABCB1 with IC(50) values of 0.07 and 3.3µM, respectively.

Formula: C₂₉H₃₂N₆O₄S
MW: 560.7 g/mol
Storage Temperature: Freezer
MDL Number: MFCD18074524
CAS Number: 950769-58-1

Order Now

Specification Test Results

Purity 95%
Appearance/Color Solid.
Solubility Soluble in DMSO. Slightly soluble (1mg/ml) in ethanol.

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR